Bone sarcomas: pathogenesis and new therapeutic approaches, IBMS BoneKEy, vol.8, issue.9, pp.402-414, 2011. ,
DOI : 10.1138/20110531
Osteosarcoma: current status of immunotherapy and future trends, Oncol. Rep, vol.15, pp.693-700, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667509
Translational biology of osteosarcoma, Translational biology of osteosarcoma, pp.722-757, 2014. ,
DOI : 10.3109/02841869509127199
Bone microenvironment signals in osteosarcoma development, Cellular and Molecular Life Sciences, vol.128, issue.2, pp.72-3097, 2015. ,
DOI : 10.1002/ijc.25331
Drugs in early clinical development for the treatment of osteosarcoma, Expert Opinion on Investigational Drugs, vol.50, issue.6, pp.1265-1280, 2016. ,
DOI : 10.1038/srep20944
URL : https://hal.archives-ouvertes.fr/inserm-01466096
Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad, STEM CELLS, vol.70, issue.3, pp.397-403, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-1305
URL : http://onlinelibrary.wiley.com/doi/10.1002/stem.596/pdf
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?, Bone, vol.62, pp.56-63, 2014. ,
DOI : 10.1016/j.bone.2014.02.003
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency, Nat. Commun, vol.6, issue.8940, 2015. ,
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations, Annals of Oncology, vol.27, issue.4, pp.27-738, 2016. ,
DOI : 10.1093/annonc/mdw009
Cancer Stem Cell Niche: The Place to Be, Cancer Research, vol.71, issue.3, pp.71-634, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-3220
Timeline: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited, Nature Reviews Cancer, vol.3, issue.6, pp.453-458, 2003. ,
DOI : 10.1038/nrc1098
Mesenchymal stroma: Role in osteosarcoma progression, Cancer Letters, vol.405, pp.90-99, 2017. ,
DOI : 10.1016/j.canlet.2017.07.024
Cancer stem cells in osteosarcoma, Cancer Letters, vol.386, pp.189-195, 2017. ,
DOI : 10.1016/j.canlet.2016.11.019
URL : https://hal.archives-ouvertes.fr/inserm-01466078
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future, Cell, vol.168, issue.4, pp.613-628, 2017. ,
DOI : 10.1016/j.cell.2017.01.018
The biology of normal bone remodelling, European Journal of Cancer Care, vol.345, issue.6 ,
DOI : 10.1038/345442a0
Mechanisms of bone repair and regeneration, Trends in Molecular Medicine, vol.15, issue.9, pp.417-446, 2009. ,
DOI : 10.1016/j.molmed.2009.07.002
Osteoclastic acidification pathways during bone resorption, Bone, vol.30, issue.4, pp.533-573, 2002. ,
DOI : 10.1016/S8756-3282(02)00672-5
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004. ,
DOI : 10.1016/j.cytogfr.2004.06.004
osteoprotegerin: key partners of osteoimmunology and vascular diseases, Cell. Mol. Life Sci, vol.4, pp.2334-2350, 2007. ,
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-176, 1998. ,
Canonical and non-canonical pathways of osteoclast formation, Histol. Histopathol, vol.24, pp.337-346, 2009. ,
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis, J. Pathol, vol.221, pp.77-86, 2010. ,
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.272, issue.6656, pp.175-179, 1997. ,
DOI : 10.1074/jbc.272.40.25190
TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell???specific Survival Factor, The Journal of Experimental Medicine, vol.372, issue.12 ,
DOI : 10.1084/jem.183.1.7
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond, Front. Immunol, vol.5, p.511, 2014. ,
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems, Nature Reviews Immunology, vol.50, issue.4, pp.292-304, 2007. ,
DOI : 10.1016/S0002-9440(10)63016-7
RANK-RANKL signalling in cancer, Bioscience Reports, vol.36, issue.4, p.366, 2016. ,
DOI : 10.1042/BSR20160150
URL : https://hal.archives-ouvertes.fr/inserm-01644732
RANKL blockade prevents and treats aggressive osteosarcomas, Science Translational Medicine, vol.31, issue.5 ,
DOI : 10.1007/s00259-003-1441-5
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, Am. J. Pathol, vol.163, pp.2021-2031, 2003. ,
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, J. Pathol, pp.211-555, 2007. ,
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models, Journal of Bone and Mineral Research, vol.390, issue.10, pp.26-2452, 2011. ,
DOI : 10.1016/j.bbrc.2009.10.020
Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization, Cancer Lett, pp.395-406, 2017. ,
DOI : 10.1016/j.canlet.2017.02.032
Monoclonal antibodies targeting RANKL in bone metastasis treatment, Monoclonal antibodies in oncology Fatih M. Uckum, eBook Future Medicine Ltd, pp.42-53, 2012. ,
RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?, Oncology, vol.88, issue.4, pp.257-260, 2015. ,
DOI : 10.1159/000369975
Increased osteoclast activity is associated with aggressiveness of osteosarcoma, Int. J. Oncol, vol.33, pp.1231-1238, 2008. ,
The role of osteoclasts and tumourassociated macrophages in osteosarcoma metastasis, Biochim. Biophys. Acta, vol.1826, pp.434-442, 2012. ,
Inflammatory Osteoclasts Prime TNF?-Producing CD4+ T Cells and Express CX3 CR1, J. Bone Miner. Res, pp.31-1899, 2016. ,
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence, PLoS One, vol.5, p.10999, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667931
Prognostic value of inflammation-based scores in patients with osteosarcoma, Scientific Reports, vol.34, issue.1, 2016. ,
DOI : 10.1111/j.1365-2796.1990.tb00262.x
Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma, FEBS Open Bio, vol.34, issue.1, pp.682-687, 2015. ,
DOI : 10.1186/s40880-015-0025-7
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, pp.78343-78354, 2016. ,
DOI : 10.18632/oncotarget.13055
URL : https://hal.archives-ouvertes.fr/inserm-01466103
Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity, Immunology, vol.69, pp.145-149, 1990. ,
Mast cells in atherosclerosis as a source of the cytokine RANKL, Clin. Chem. Lab. Med, vol.44, pp.672-674, 2006. ,
Mast cells are critical regulators of bone fracture-induced inflammation and osteoclast formation and activity, J. Bone Miner. Res ,
Tumor-associated mesenchymal stromal cells promote osteosarcoma stemness and migratory potential via IL-6 secretion, PLoS One, pp.11-0166500, 2016. ,
DOI : 10.1371/journal.pone.0166500
URL : https://doi.org/10.1371/journal.pone.0166500
Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3, Oncotarget, vol.7, issue.30, pp.48296-48308, 2016. ,
DOI : 10.18632/oncotarget.10219
Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion, World Journal of Surgical Oncology, vol.13, issue.1, p.13, 2015. ,
DOI : 10.1155/2011/959248
URL : https://wjso.biomedcentral.com/track/pdf/10.1186/s12957-015-0465-1?site=wjso.biomedcentral.com
Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip, Eur, J. Cell. Biol, vol.96, pp.110-118, 2017. ,
Mesenchymal/stem stromal cells under stress increase osteosarcoma migration and apoptosis resistance via extracellular resistance via extracellular vesicle mediated communication, PLoS One, vol.11, p.166027, 2016. ,
Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-?B activation, Int. J. Cancer, vol.140, pp.1331-1345, 2017. ,
Multimodal transfer of MDR by exosomes in human osteosarcoma, International Journal of Oncology, vol.49, issue.1, pp.189-96, 2016. ,
DOI : 10.3892/ijo.2016.3509
Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment, Journal of Inflammation Research, vol.9, pp.231-240, 2016. ,
DOI : 10.2147/JIR.S121994
Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide, Cell Stem Cell, vol.2, issue.2, pp.141-150, 2008. ,
DOI : 10.1016/j.stem.2007.11.014
Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization, STEM CELLS Translational Medicine, vol.194, issue.3, pp.1018-1028, 2017. ,
DOI : 10.4049/jimmunol.1401420
Macrophages and skeletal health, Pharmacology & Therapeutics, vol.174, pp.3-54, 2017. ,
DOI : 10.1016/j.pharmthera.2017.02.017
Proteoglycans and osteolysis, Methods Mol. Biol, vol.836, pp.323-337, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667515
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling, Stem Cells, vol.30, pp.762-772, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00668995
Alternative Activation of Macrophages: Mechanism and Functions, Immunity, vol.32, issue.5, pp.593-604, 2010. ,
DOI : 10.1016/j.immuni.2010.05.007
Distinct Role of Macrophages in Different Tumor Microenvironments, Cancer Research, vol.66, issue.2, pp.605-612, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-4005
Tumor-Associated Macrophages: From Mechanisms to Therapy, Immunity, vol.41, issue.1, pp.49-61, 2014. ,
DOI : 10.1016/j.immuni.2014.06.010
URL : https://doi.org/10.1016/j.immuni.2014.09.021
Macrophage Diversity Enhances Tumor Progression and Metastasis, Cell, vol.141, issue.1, pp.39-51, 2010. ,
DOI : 10.1016/j.cell.2010.03.014
URL : https://doi.org/10.1016/j.cell.2010.03.014
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clinical Cancer Research, vol.17, issue.8, pp.2110-2119, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2047
CD163+ M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma, International Immunopharmacology, vol.34, pp.101-106, 2016. ,
DOI : 10.1016/j.intimp.2016.01.023
Increased CTLA-4 + T cells and an increased ratio of monocytes with loss of class II (CD14 + HLA-DR lo/neg ) found in aggressive pediatric sarcoma patients, J. Immunother. Cancer, vol.3, issue.35, 2015. ,
Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients, International Immunopharmacology, vol.44, pp.44153-159, 2017. ,
DOI : 10.1016/j.intimp.2017.01.006
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment, International Journal of Cancer, vol.1, issue.Suppl3, pp.73-85, 2015. ,
DOI : 10.1158/2159-8274.CD-10-0028
Improved survival in osteosarcoma patients with atypical low vascularisation ,
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Review of Anticancer Therapy, vol.168, issue.2, pp.151-159, 2008. ,
DOI : 10.1016/S0022-5347(05)64148-1
Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opinion on Pharmacotherapy, vol.50, issue.1, pp.285-292, 2011. ,
DOI : 10.1007/BF01741788
URL : https://hal.archives-ouvertes.fr/inserm-00667530
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-??, Journal of Experimental & Clinical Cancer Research, vol.33, issue.1, 2014. ,
DOI : 10.1126/science.1198443
All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages, Cancer Immunol. Res, vol.5, pp.547-559, 2017. ,
Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumorassociated macrophages and/or G1 arrest in tumor cells, Eur. J. Pharmacol, pp.746-115, 2015. ,
Oncolytic adnovirus as a therapeutic approach for osteosarcoma: a new hope, J. Bone Oncol ,
Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation, Cancer Res, vol.73, pp.490-495, 2013. ,
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma, Scientific Reports, vol.112, issue.1, 2016. ,
DOI : 10.1002/cncr.23437
CD8 + /FOXP3 + ration in osteosarcoma microenvironment separates survivors from non-survivors: a multicentre validated retrospective study, p.990800, 2015. ,
Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma, Journal of Veterinary Internal Medicine, vol.123, issue.1-2, pp.24-1118, 2010. ,
DOI : 10.4049/jimmunol.172.8.4752
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer, Molecular Oncology, vol.33, issue.Suppl. 1, 1918. ,
DOI : 10.1200/JCO.2014.60.6566
Exploiting the curative potential of adoptive T-cell therapy for cancer, Immunological Reviews, vol.2, issue.1, pp.56-71, 2014. ,
DOI : 10.1182/blood-2009-02-203935
Phenotypic and functional analysis of 3ymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype, Cancer Immunol. Immunother, pp.34-241, 1992. ,
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.17, issue.1, 2005. ,
DOI : 10.1080/08880010050034283
The B7 Family and Cancer Therapy: Costimulation and Coinhibition, Clinical Cancer Research, vol.13, issue.18, pp.5271-5279, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-1030
URL : http://clincancerres.aacrjournals.org/content/clincanres/13/18/5271.full.pdf
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family, Immunity, vol.44, issue.5, pp.955-972, 2016. ,
DOI : 10.1016/j.immuni.2016.05.002
Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice, Genetics and Molecular Research, vol.14, issue.4, pp.14253-61, 2015. ,
DOI : 10.4238/2015.November.13.9
B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis, PLoS ONE, vol.283, issue.8, p.70689, 2013. ,
DOI : 10.1371/journal.pone.0070689.s001
Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors, Pediatr. Blood Cancer in press ,
Programmed Cell Death Ligand 1 Expression in Osteosarcoma, Cancer Immunology Research, vol.2, issue.7, pp.690-698, 2014. ,
DOI : 10.1158/2326-6066.CIR-13-0224
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy, Cancer Immunol. Immunother, pp.66-119, 2017. ,
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent ,
Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis, Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma, p.157176, 1994. ,
DOI : 10.18632/oncotarget.19168
Expression of programmed death 1 is correlated with progression of osteosarcoma, APMIS, vol.37, issue.2, pp.102-107, 2015. ,
DOI : 10.1007/s10753-013-9718-8
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions, J. Immunother, pp.38-96, 2015. ,
Potential of human ???? T cells for immunotherapy of osteosarcoma, Molecular Biology Reports, vol.15, issue.1, pp.427-437, 2013. ,
DOI : 10.1002/jor.1100150119
Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004. ,
DOI : 10.1016/j.molmed.2004.05.007
Trastuzumab enhanced the cytotoxicity of V??9V??2 T cells against zoledronate-sensitized osteosarcoma cells, International Immunopharmacology, vol.28, issue.1, pp.28-160, 2015. ,
DOI : 10.1016/j.intimp.2015.06.002
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells, Cellular Immunology, vol.249, issue.2, pp.63-72, 2007. ,
DOI : 10.1016/j.cellimm.2007.11.005
Sensitization of human osteosarcoma cells to V??9V??2 T-cell-mediated cytotoxicity by zoledronate, Journal of Orthopaedic Research, vol.171, issue.5, pp.824-830, 2012. ,
DOI : 10.4049/jimmunol.171.5.2402
IFN-?? enhances HOS and U2OS cell lines susceptibility to ???? T cell-mediated killing through the Fas/Fas ligand pathway, International Immunopharmacology, vol.11, issue.4, pp.11-496, 2011. ,
DOI : 10.1016/j.intimp.2011.01.001
???? T Cells: Unexpected Regulators of Cancer Development and Progression, Trends in Cancer, vol.3, issue.8, pp.561-570, 2017. ,
DOI : 10.1016/j.trecan.2017.06.003
Genetically Modified T-Cell Therapy for Osteosarcoma, Adv. Exp. Med. Biol, vol.804, pp.323-340, 2014. ,
DOI : 10.1007/978-3-319-04843-7_18
Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression, Molecular Therapy, vol.17, issue.10, pp.1779-1787, 2009. ,
DOI : 10.1038/mt.2009.133
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumorinitiating cells in osteosarcoma, Cancer Gene Ther, vol.19, pp.212-217, 2012. ,
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats, Cancer Res, vol.68, pp.9433-9440, 2008. ,
In??????vitro generation of cytotoxic T??????lymphocyte response using dendritic cell immunotherapy in osteosarcoma, Oncology Letters, pp.12-1101, 2016. ,
DOI : 10.3892/ol.2016.4714
Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma, Oncology Reports, vol.34, issue.4, p.34, 1995. ,
DOI : 10.3892/or.2015.4161
Anti-TGF-?? Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma, Clinical Orthopaedics and Related Research??, vol.16, issue.8, pp.470-2288, 2012. ,
DOI : 10.1158/1078-0432.CCR-09-1634
Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response, Genetics and Molecular Research, vol.14, issue.4, pp.11763-11770, 2015. ,
DOI : 10.4238/2015.October.2.10
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma, Cancer Immunol. Immunother, vol.64, pp.1251-1260, 2015. ,
Natural Killer Cells for Osteosarcoma, Adv. Exp. Med. Biol, vol.804, pp.341-353, 2014. ,
DOI : 10.1007/978-3-319-04843-7_19
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D???NKG2DL dependent manner, Cancer Letters, vol.368, issue.1, pp.54-63, 2015. ,
DOI : 10.1016/j.canlet.2015.07.042
Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect, Methods Mol. Biol, vol.17, issue.6, pp.1441-285, 2016. ,
DOI : 10.1023/A:1006623001465
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells, Cancer Immunology, Immunotherapy, vol.45, issue.4, pp.60-575, 2011. ,
DOI : 10.1186/1471-2407-9-186
URL : http://doi.org/10.1007/s00262-010-0965-3
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis, Pediatric Blood & Cancer, vol.190, issue.8, pp.61-1362, 2014. ,
DOI : 10.4049/jimmunol.1201314
Invariant NKT cells increase drug-induced osteosarcoma cell death, British Journal of Pharmacology, vol.192, issue.7, pp.1533-1549, 2012. ,
DOI : 10.4049/jimmunol.1001018
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02108.x/pdf
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models, Cancer Research, vol.73, issue.17, pp.5315-5319, 2013. ,
DOI : 10.1158/0008-5472.CAN-13-1069
URL : http://cancerres.aacrjournals.org/content/canres/73/17/5315.full.pdf
Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts, Nature Reviews Cancer, vol.111, issue.8, pp.451-452, 2015. ,
DOI : 10.1016/S0092-8674(02)01229-1
Patient-Derived Mouse Models of Cancer Molecular and Translational Medicine Series, 2017. ,
Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics, Genome Med, vol.6, issue.116, 2014. ,
A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology, Oncotarget, vol.8, pp.62111-62119, 2017. ,
Establishment of a patient-derived orthotopic osteosarcoma mouse model, Journal of Translational Medicine, vol.6, issue.2, 2015. ,
DOI : 10.1186/1748-717X-6-119
Tumortargeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug, Oncotarget, vol.8, pp.8035-8042, 2017. ,
Intra-arterial administration of tumortargeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model, Cell Cycle, vol.16, pp.1164-1170, 2017. ,
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model, Nat. Commun, vol.8, p.707, 2017. ,